A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs TSR 033 (Primary) ; TSR 042 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CITRINO
  • Sponsors TESARO
  • Most Recent Events

    • 03 May 2018 According to a TESARO media release, the Company expects to initiate assessment in Q2 2018 and report Phase 1 monotherapy dose-escalation data for TSR-033 in 2H 2018.
    • 27 Feb 2018 According to TESARO media release, the Company expects to report monotherapy dose-escalation data in 2H 2018.
    • 10 Aug 2017 According to an AnaptysBio media release, TESARO received clearance of an Investigational New Drug application (IND) for TSR-033.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top